These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22878814)

  • 21. Development of a novel direct compressible co-processed excipient and its application for formulation of Mirtazapine orally disintegrating tablets.
    Loke YH; Chew YL; Janakiraman AK; Lee SK; Uddin ABMH; Goh CF; Kee PE; Ng HS; Ming LC; Liew KB
    Drug Dev Ind Pharm; 2024 Jan; 50(1):36-44. PubMed ID: 38149637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and evaluation of microwave-treated orally disintegrating tablets containing polymeric disintegrant and mannitol.
    Sano S; Iwao Y; Noguchi S; Kimura S; Itai S
    Int J Pharm; 2013 May; 448(1):132-41. PubMed ID: 23524122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation about wettability, water absorption or swelling of excipients through various methods and the correlation between these parameters and tablet disintegration.
    Yang B; Wei C; Yang Y; Wang Q; Li S
    Drug Dev Ind Pharm; 2018 Sep; 44(9):1417-1425. PubMed ID: 29557692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
    Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
    Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships between response surfaces for tablet characteristics of placebo and API-containing tablets manufactured by direct compression method.
    Hayashi Y; Tsuji T; Shirotori K; Oishi T; Kosugi A; Kumada S; Hirai D; Takayama K; Onuki Y
    Int J Pharm; 2017 Oct; 532(1):82-89. PubMed ID: 28859939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Prosolv and Prosolv:Mannitol 200 direct compression fillers on the physicomechanical properties of atorvastatin oral dispersible tablets.
    Gowda V; Pabari RM; Kelly JG; Ramtoola Z
    Pharm Dev Technol; 2015 Jun; 20(4):394-400. PubMed ID: 24397821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Latent structure analysis in pharmaceutical formulations using Kohonen's self-organizing map and a Bayesian network.
    Kikuchi S; Onuki Y; Yasuda A; Hayashi Y; Takayama K
    J Pharm Sci; 2011 Mar; 100(3):964-75. PubMed ID: 21355105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesoporous Pravastatin Solid Dispersion Granules Incorporable Into Orally Disintegrating Tablets.
    Song H; Moon C; Lee BJ; Oh E
    J Pharm Sci; 2018 Jul; 107(7):1886-1895. PubMed ID: 29530714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amorphous Formulation and in Vitro Performance Testing of Instantly Disintegrating Buccal Tablets for the Emergency Delivery of Naloxone.
    Alqurshi A; Kumar Z; McDonald R; Strang J; Buanz A; Ahmed S; Allen E; Cameron P; Rickard JA; Sandhu V; Holt C; Stansfield R; Taylor D; Forbes B; Royall PG
    Mol Pharm; 2016 May; 13(5):1688-98. PubMed ID: 26977787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The preparation of orally disintegrating tablets using a hydrophilic waxy binder.
    Abdelbary G; Prinderre P; Eouani C; Joachim J; Reynier JP; Piccerelle P
    Int J Pharm; 2004 Jul; 278(2):423-33. PubMed ID: 15196646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A methodological evaluation and predictive in silico investigation into the multi-functionality of arginine in directly compressed tablets.
    ElShaer A; Kaialy W; Akhtar N; Iyire A; Hussain T; Alany R; Mohammed AR
    Eur J Pharm Biopharm; 2015 Oct; 96():272-81. PubMed ID: 26255158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
    Mostafa HF; Ibrahim MA; Sakr A
    Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of non-water-soluble placebo pellets of different sizes on the characteristics of orally disintegrating tablets manufactured by freeze-drying.
    Stange U; Führling C; Gieseler H
    J Pharm Sci; 2013 Jun; 102(6):1786-1799. PubMed ID: 23568590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence-based nanoscopic and molecular framework for excipient functionality in compressed orally disintegrating tablets.
    Al-Khattawi A; Alyami H; Townsend B; Ma X; Mohammed AR
    PLoS One; 2014; 9(7):e101369. PubMed ID: 25025427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets.
    Pabari RM; Ramtoola Z
    Int J Pharm; 2012 Jul; 430(1-2):18-25. PubMed ID: 22465631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling of latent structure of indomethacin solid dispersion tablet using Bayesian networks.
    Hayashi Y; Kikuchi S; Takayama K
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1290-7. PubMed ID: 21702729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization, optimisation and process robustness of a co-processed mannitol for the development of orally disintegrating tablets.
    Soh JL; Grachet M; Whitlock M; Lukas T
    Pharm Dev Technol; 2013 Feb; 18(1):172-85. PubMed ID: 22582882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roll compaction of mannitol: compactability study of crystalline and spray-dried grades.
    Wagner CM; Pein M; Breitkreutz J
    Int J Pharm; 2013 Sep; 453(2):416-22. PubMed ID: 23742975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early detection of capping risk in pharmaceutical compacts.
    Xu X; Vallabh CKP; Hoag SW; Dave VS; Cetinkaya C
    Int J Pharm; 2018 Dec; 553(1-2):338-348. PubMed ID: 30367987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of co-processed excipients used for direct compression of orally disintegrating tablets (ODT) using novel disintegration apparatus.
    Brniak W; Jachowicz R; Krupa A; Skorka T; Niwinski K
    Pharm Dev Technol; 2013; 18(2):464-74. PubMed ID: 22881600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.